Sentinels / Actor desk
Quarter For Gilead Sciences
organization · Registry status: unverified
cbb58eb9-1a68-5aca-8853-26b902e1074e
Evidence, not intent.
Public-source event mentions and stored signals. Adjacency does not establish causation, coordination, or an actor's position.
No claim of complete coverage or live monitoring.
Observation window
UTC dates, inclusive · maximum 90 days. Applies to events and anomalies only.
Recent observations / timeline
The source record
194 distinct events shown, newest first. Headlines may be generated summaries; inspect the source before repeating a claim.
Approval of a cheap version of HIV-prevention shot lenacapavir raises hopes in low-income countries
Gilead Sciences (NASDAQ:GILD) CEO Sells $2,546,100.00 in Stock
Gilead Sciences (NASDAQ:GILD) Stock: Insider Daniel Patrick O’day Sells 15,881 Shares
thebusinessjournal.com: Gerald Imray, Saiqa Mullick, Drug Administration (wb 845 legal and regulatory framework, wb 845 legal and regulatory framework)
Approval of India-made version of HIV-prevention shot lenacapavir raises hopes in low-income countries - Daily Excelsior
Approval of a cheap version of HIV-prevention shot lenacapavir raises hopes in low-income countries - WWAYTV3
cbc.ca: Thandeka Shabangu, Kayleen Morgan, Drug Administration (crisislex c03 wellbeing health, crisislex c03 wellbeing health)
US approves cheap generic version of world’s only twice-yearly HIV prevention jab
Collect More Income From the Savings You Already Have, Without Selling What You Built.
Dr Reddy's gets tentative US FDA nod for generic HIV prevention - News India Times
Dr Reddy's Gets Tentative US FDA Nod for Generic HIV Prevention
Approval of a cheap version of HIV-prevention shot lenacapavir raises hopes in low-income countries - WCCB Charlotte
Approval of a cheap version of HIV-prevention shot lenacapavir raises hopes in low-income countries
FDA approves generic version of HIV-prevention drug to be sold in low-income countries
FDA approves more affordable version of HIV-prevention shot
FDA approves generic version of HIV-prevention drug to be sold in low-income countries
FDA approves generic version of HIV-prevention drug to be sold in low-income countries
FDA approves generic version of HIV-prevention drug to be sold in low-income countries
Approval of India-made version of HIV-prevention shot raises hopes in low-income countries - The Tribune
Approval of a cheap version of HIV-prevention shot lenacapavir raises hopes in low-income countries
Approval of a cheap version of HIV-prevention shot lenacapavir raises hopes in low-income countries
FDA approves generic version of HIV-prevention drug to be sold in low-income countries
Approval of a cheap version of HIV-prevention shot lenacapavir raises hopes in low-income countries
FDA approves generic version of HIV-prevention drug to be sold in low-income countries
FDA approves generic version of HIV-prevention drug to be sold in low-income countries
US approves cheap version of HIV prevention shot
FDA approves more affordable version of HIV-prevention shot
Approval of a generic HIV-prevention shot raises hopes in low-income countries
Approval of a cheap version of HIV-prevention shot lenacapavir raises hopes in low-income countries
Approval of cheap version of HIV-prevention shot raises hopes in low-income countries
FDA approves generic version of HIV-prevention drug to be sold in low-income countries
FDA approves generic version of HIV-prevention drug to be sold in low-income countries
Approval of a cheap version of HIV-prevention shot lenacapavir raises hopes in low-income countries
FDA approves generic version of HIV-prevention drug to be sold in low-income countries
business-standard.com: Philippe Duneton, Deepak Sapra, World Health Organization (tax fncact chief executive, tax fncact director)
Approval of a cheap version of HIV-prevention shot lenacapavir raises hopes in low-income countries
Approval of a cheap version of HIV-prevention shot lenacapavir raises hopes in low-income countries
FDA approves more affordable version of HIV-prevention shot
Approval of a generic HIV-prevention shot raises hopes in low-income countries
FDA approves generic version of HIV-prevention drug to be sold in low-income countries
How Trump Destroyed South Africa’s Effort to Slow HIV Transmission
FDA approves generic version of HIV-prevention drug to be sold in low-income countries
Approval of a cheap version of HIV-prevention shot lenacapavir raises hopes in low-income countries
FDA approves generic version of HIV-prevention drug to be sold in low-income countries
Approval of a cheap version of HIV-prevention shot lenacapavir raises hopes in low-income countries
Approval of a cheap version of HIV-prevention shot lenacapavir raises hopes in low-income countries
FDA approves more affordable version of HIV-prevention shot
FDA approves generic version of HIV-prevention drug to be sold in low-income countries
FDA approval of cheap version of HIV-prevention shot lenacapavir raises hopes in low-income countries
Approval of a cheap version of HIV-prevention shot lenacapavir raises hopes in low-income countries
Approval of a cheap version of HIV-prevention shot lenacapavir raises hopes in low-income countries - myMotherLode.com
Approval of a cheap version of HIV-prevention shot lenacapavir raises hopes in low-income countries
FDA approves generic version of HIV-prevention drug to be sold in low-income countries
FDA approves generic version of HIV-prevention drug to be sold in low-income countries
FDA approves generic version of HIV-prevention drug to be sold in low-income countries
Approval of a cheap version of HIV-prevention shot lenacapavir raises hopes in low-income countries
Approval of a cheap version of HIV-prevention shot lenacapavir raises hopes in low-income countries
moneycontrol.com: Deepak Sapra, Public Health Access, Gilead Sciences (general health, general health)
Former Gilead Head of U.S. Medical Affairs Dean Hakanson, MD, Joins GOA Therapeutics as Chief Medical Officer
Approval of a cheap version of HIV-prevention shot lenacapavir raises hopes in low-income countries
Approval of a cheap version of HIV-prevention shot lenacapavir raises hopes in low-income countries
Approval of a cheap version of HIV-prevention shot lenacapavir raises hopes in low-income countries
Approval of a cheap version of HIV-prevention shot lenacapavir raises hopes in low-income countries
Approval of a cheap version of HIV-prevention shot lenacapavir raises hopes in low-income countries
Approval of a cheap version of HIV-prevention shot lenacapavir raises hopes in low-income countries
Approval of a cheap version of HIV-prevention shot lenacapavir raises hopes in low-income countries
FDA approves more affordable version of HIV-prevention shot
Approval of a cheap version of HIV-prevention shot lenacapavir raises hopes in low-income countries
Approval of a cheap version of HIV-prevention shot lenacapavir raises hopes in low-income countries
Approval of a cheap version of HIV-prevention shot lenacapavir raises hopes in low-income countries
Approval of a cheap version of HIV-prevention shot lenacapavir raises hopes in low-income countries - Netscape News
Approval of a cheap version of HIV-prevention shot lenacapavir raises hopes in low-income countries
Approval of a cheap version of HIV-prevention shot lenacapavir raises hopes in low-income countries
Approval of a cheap version of HIV-prevention shot lenacapavir raises hopes in low-income countries
Approval of a cheap version of HIV-prevention shot lenacapavir raises hopes in low-income countries
Approval of a cheap version of HIV-prevention shot lenacapavir raises hopes in low-income countries
Approval of a cheap version of HIV-prevention shot lenacapavir raises hopes in low-income countries
Gilead Sciences, Inc.: Gilead to Present Late-Breaking Clinical Data and Real-World Evidence at HIV Glasgow
Gilead Sciences (NASDAQ:GILD) Price Target Raised to $190.00
BioMarin Pharmaceutical (BMRN) Q3 earnings: what to expect
1 Dividend-Paying Biotech Stock to Buy Hand Over Fist in November | The Motley Fool
Promising Healthcare Stocks To Research – November 1st
Biotech Stocks To Keep An Eye On – October 30th
Best Medical Stocks To Keep An Eye On – October 30th
What Gilead Sciences (GILD) Said on Its Q3 Earnings Call
Promising Pharmaceutical Stocks To Follow Today – October 31st
VIRGINIA RETIREMENT SYSTEMS ET Al Sells 507,868 Shares of Gilead Sciences, Inc. $GILD
Cognizant (NASDAQ: CTSH) adjusted margin widens, but third-quarter bookings fall 7%
morningstar.com: Gilead Sciences (wb 1921 private sector development, wb 346 competitive industries)
How to keep your wealth growing as investors brace for market meltdown
Futures Slide As AI Reckoning Claims Amazon, Intel; Oil Jumps On Hormuz Tanker Hits
GILD Q3 deep dive: HIV franchise drives growth as policy headwinds loom
Intel Drops 29% at the Open as Pharma Stocks Lead Gainers
Morning Kickstart: Tech hammered as Amazon and Intel tumble; oil rises despite peace talk
MARKETS LIVE: Wall Street closes lower as Alphabet sell-off revives AI spending concerns
infotechlead.com: Ravi Kumar, Financial Services Revenue Growth, Cognizant Health Sciences (wb 838 public accountability mechanisms, tax fncact agents)
Cognizant Q3 Earnings: ‘We View Agentic AI As The Most Significant Enterprise Opportunity Since Digitization,’ Says CEO
seekingalpha.com: Gilead Sciences
Gilead Hits A Record High, Notches Best Growth In A Decade
Amazon and Intel headline the earnings releases after today’s close
Cognizant (CTSH) Q3 2026 Earnings Call Transcript - AOL
Cognizant (CTSH) Q3 2026 Earnings Call Transcript | The Motley Fool
Here are the major earnings after the close Thursday
Breakfast News: Brace for an AI Optics Shake-up | The Motley Fool
Kymera Therapeutics Announces Third Quarter 2026 Financial Results and Reports Positive Results from the KT-579 Phase 1 Healthy Volunteer Trial
Before the Bell: What every Canadian investor needs to know today
Bay Area food banks, farms mobilize to better feed families in need
Biopharma sector adds new finance leaders
African health experts urge immediate action over new Ebola cases
Best Biotech Stocks Worth Watching – October 26th
Invesco’s RSPH or iShares’ IBB: Which Healthcare ETF Is the Better Long-Term Buy? | The Motley Fool
Invesco’s RSPH or iShares’ IBB: Which Healthcare ETF Is the Better Long-Term Buy? | The Motley Fool
Ebola spread prompts call for coordinated African response
Google, Microsoft, Amazon, and the Fed step up to a skittish market: What to watch this week - AOL
Here are 4 big things we're watching in the stock market this week
Best Pharmaceutical Stocks To Watch Today – October 24th
VanEck Biotech vs. Invesco Healthcare: Which ETF Offers More Potential for Long-Term Growth? | The Motley Fool
Amgen vs. Gilead Sciences: Which Biotech Dividend Stock Is the Better Buy? | The Motley Fool
VanEck Biotech vs. Invesco Healthcare: Which ETF Offers More Potential for Long-Term Growth? | The Motley Fool
Amgen vs. Gilead Sciences: Which Biotech Dividend Stock Is the Better Buy? - AOL
Durvalumab Plus BCG Improves DFS in Papillary-Only, BCG-Naive High-Risk NMIBC in POTOMAC | OncLive
HIV prevention jab offers hope in Uganda but doses are hard to find | Africanews
7,751 Shares in Gilead Sciences, Inc. $GILD Bought by NBT Bank N.A.
NBT Bank N.A. Buys 7,751 Shares of Gilead Sciences, Inc. $GILD
Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy? | The Motley Fool
Biotech stocks are surging. How investors can play the new drug innovation boom
Sacituzumab Govitecan Triplet Elicits Durable Responses in Treatment-Naive Metastatic Urothelial Cancer | OncLive
Dr. Reddy's (RDY) Q2 2027 Earnings Call Transcript | The Motley Fool
Analyzing Inhibrx Biosciences (NASDAQ:INBX) and Ligand Pharmaceuticals (NASDAQ:LGND)
Best Biotech Stocks To Keep An Eye On – October 23rd
moneycontrol.com: Gilead Sciences, Drug Administration, United States (tax disease hiv, tax fncact managing director)
Invesco Pharmaceuticals ETF vs. iShares Biotechnology ETF: Which Is the Better Buy? | The Motley Fool
Gilead to buy PepStar's inflammation drug program in $1.28 billion deal
econotimes.com: Gilead Sciences, Drug Administration, Bristol Myers Squibb (tax fncact regulators, tax disease breast cancer)
Study: Most who switch to long-acting HIV therapy stick with it
BioNTech Expands Phase 3 Breast Cancer Trial Through Collaboration With Gilead
BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead’s TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer | Company Announcement | Investegate
BioNTech SE: BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead's TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer
Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy? | The Motley Fool
Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy? | The Motley Fool
Macrolide Resistance Common in M genitalium Infections
26,071 Shares of Roivant Sciences Ltd. $ROIV Purchased by Englebert Financial Advisers LLC
Gilead Sciences, Inc. $GILD Stock: Range Financial Group LLC Boosts Holdings
Metabolic Dysfunction-Associated Steatohepatitis Clinical Trial and Competitive Landscape Expands as 180+ Companies Target New Treatment Options | DelveInsight
Belgian startup revives Galapagos CAR-T research
Credence Research Inc.: Antiviral Drugs Market to Reach USD 125.26 Billion by 2035 - Credence Research
Antiviral Drugs Market to Reach USD 125.26 Billion by 2035 - Credence Research
Obesity Clinical Trial and Competitive Landscape Surges as 200+ Companies Advance Next-Generation Therapies | DelveInsight
Gilead Sciences Clears Its February High at $153.54
Stock Market Movers: Best and Worst Performers of 14 October 2026
J&J earnings set ‘negative tone’; Shkreli vs. the FTC
Vir Biotechnology Partners With Gilead On Next-Generation Cancer Immunotherapy Programs
Gilead Sciences, Inc. $GILD Stock Position Boosted by First Citizens Bank & Trust Co.
Gilead Sciences, Inc. $GILD Stock Acquired by First Citizens Bank & Trust Co.
Blockbuster Drugs Come and Go. These 5 Pharma Dividend Stocks Keep Paying - AOL
Blockbuster Drugs Come and Go. These 5 Pharma Dividend Stocks Keep Paying
Promising Pharmaceutical Stocks To Follow Now – October 11th
Medical Marijuana Clinical Trial Landscape Expands as 60+ Leading Companies Accelerate Drug Development | DelveInsight
Medical Health & Life Science Research News
Specialty Pharmaceutical Market Size, Share, Growth, Trends and Forecast to 2035
Medical Health & Life Science Research News
Viatris to Acquire Pacira in US$1.65bn Pain Management Deal
Which Pharmaceuticals ETF Is the Better Buy: iShares’ IHE or Invesco’s PJP? | The Motley Fool
Which Pharmaceuticals ETF Is the Better Buy: iShares’ IHE or Invesco’s PJP? | The Motley Fool
Which iShares Healthcare ETF Is the Better Buy: Biotech-Focused IBB or Broad IYH? | The Motley Fool
Promising Pharmaceutical Stocks To Follow Now – October 11th
Better Invesco Healthcare ETF: PJP Targeting Pharmaceuticals vs. RSPH's Broader Sector Lens | The Motley Fool
Better Biotechnology ETF: First Trust FBT vs. VanEck BBH | The Motley Fool
Better Biotechnology ETF: First Trust FBT vs. VanEck BBH | The Motley Fool
Better Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting Pharma | The Motley Fool
Medical Stocks To Follow Now – October 10th
Medical Stocks To Follow Now – October 10th
Better Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting Pharma | The Motley Fool
Top Biotech Stocks To Watch Now – October 10th
Weekly Buzz: RHHBY, NVS, PFE Win FDA Nod; CRBU Scales Back; PCVX, ABBV Report Positive Trial Data
Long-Acting HIV Treatment Holds Up in South African Youth
Stock Analysts’ Updated EPS Estimates for October 8th (AGCO, AGT, BOKU, BPT, CAML, CAVA, CHYM, CNTB, CRBU, CRE)
Head to Head Review: Gilead Sciences (NASDAQ:GILD) versus GRAIL (NASDAQ:GRAL)
Insider Selling: Sight Sciences (NASDAQ:SGHT) CTO Sells $70,562.85 in Stock
Why Alcohol-Associated Liver Disease May Not Have Peaked, With Brian Lee, MD | HCPLive
Gilead Sciences signs five-year DevOps agreement with Cognizant
Cognizant Extends Gilead Sciences Partnership For Five Years To Scale AI-Driven DevOps
Report: Gaps in eczema diagnosis, care persist nationwide
Breast Cancer Research Foundation Fund launches venture philanthropy fund
Ebola science race: Vaccines and drugs tested against Bundibugyo virus
MELANATED MOMENTS: September Kicked Of Q4 With Style And Purpose
These stocks could benefit from a midterm election shake-up, JPMorgan says
Baltimore startup developing ‘pain sponge’ therapy closes pre-seed funding round
Jim Cramer Likes Medtronic (MDT) at 14x Earnings — So Why Isn’t He Buying More?
Nurix Extends Gilead Oncology Research Collaboration For Two Years
NC State honors Agilent’s Joydeep Ganguly for professional achievement
Head-To-Head Survey: Gilead Sciences (NASDAQ:GILD) & BridgeBio Pharma (NASDAQ:BBIO)
Better Healthcare ETF: Vanguard's Broad VHT vs. the iShares Biotechnology-Focused IBB | The Motley Fool
Better Healthcare ETF: Vanguard's Broad VHT vs. the iShares Biotechnology-Focused IBB | The Motley Fool
Signals to inspect
Anomalies
Latest 10 in the selected window (up to 10). Detector output, not verified conclusions.
New connection: 1 previously unseen co-actor(s) detected (known network: 292)
Volume spike: 31 events in window (16.1x baseline of 1.9 expected)
Coordination signal: co-actor 30df0006-4d07-589b-bab3-5c306969c7ad appeared in 3 of 5 window events (60%)
Coordination signal: co-actor 30df0006-4d07-589b-bab3-5c306969c7ad appeared in 8 of 10 window events (80%)
Volume spike: 6 events in window (3.5x baseline of 1.7 expected)
Volume spike: 9 events in window (5.1x baseline of 1.8 expected)
Coordination signal: co-actor 30df0006-4d07-589b-bab3-5c306969c7ad appeared in 4 of 6 window events (67%)
Volume spike: 4 events in window (2.3x baseline of 1.7 expected)
New connection: 11 previously unseen co-actor(s) detected (known network: 284)
Narrative context
Unresolved threads
Latest 20 at most, across all dates. Stored narratives require human review.
No unresolved threads recorded.
Stored connections
Relationships
Up to 50 records ordered by evidence count, across all dates. Co-mentions indicate association in source material, not affiliation or coordination.
- Nasdaq→ co mention →Quarter For Gilead Sciences209 evidence records
- Quarter For Gilead Sciences→ co mention →United States Senate197 evidence records
- Drug Enforcement Administration→ co mention →Quarter For Gilead Sciences176 evidence records
- Global Fund To Fight→ co mention →Quarter For Gilead Sciences174 evidence records
- News Ratings For Iveda Solutions Daily→ co mention →Quarter For Gilead Sciences139 evidence records
- Quarter For Gilead Sciences→ co mention →Securities and Exchange Commission130 evidence records
- Health Ministry→ co mention →Quarter For Gilead Sciences123 evidence records
- Quarter For Gilead Sciences→ co mention →Eli Lilly111 evidence records
- Global Health Equity→ co mention →Quarter For Gilead Sciences108 evidence records
- Pfizer→ co mention →Quarter For Gilead Sciences104 evidence records
- Quarter For Gilead Sciences→ co mention →United Nations103 evidence records
- Doctors Without Borders→ co mention →Quarter For Gilead Sciences102 evidence records
- Flavia Matovu Kiweewa→ co mention →Quarter For Gilead Sciences99 evidence records
- Instagram→ co mention →Quarter For Gilead Sciences99 evidence records
- Kamba Amiri→ co mention →Quarter For Gilead Sciences98 evidence records
- Ronald G Munro→ co mention →Quarter For Gilead Sciences98 evidence records
- Quarter For Gilead Sciences→ co mention →Clyde Russellan Asia98 evidence records
- University Of Minnesota Launch Sponsored Research Collaboration→ co mention →Quarter For Gilead Sciences98 evidence records
- Martin Mathlete→ co mention →Quarter For Gilead Sciences98 evidence records
- Goldiano Kivumbi→ co mention →Quarter For Gilead Sciences98 evidence records
- Omphile Ramokhoase Clinton Health Access Initiative→ co mention →Quarter For Gilead Sciences98 evidence records
- Kato Kintu→ co mention →Quarter For Gilead Sciences98 evidence records
- Michal Ruprecht→ co mention →Quarter For Gilead Sciences98 evidence records
- Pulitzer Centerand→ co mention →Quarter For Gilead Sciences97 evidence records
- News Global Health Media Fellowship→ co mention →Quarter For Gilead Sciences94 evidence records
- Quarter For Gilead Sciences→ co mention →Oakland University William Beaumont School Of Medicine94 evidence records
- Amgen→ co mention →Quarter For Gilead Sciences89 evidence records
- World Health Organization→ co mention →Quarter For Gilead Sciences83 evidence records
- Bristol Myers Squibb→ co mention →Quarter For Gilead Sciences81 evidence records
- Johanna Meyer→ co mention →Quarter For Gilead Sciences80 evidence records
- Quarter For Gilead Sciences→ co mention →Complera Eviplera75 evidence records
- Astrazeneca→ co mention →Quarter For Gilead Sciences66 evidence records
- Novartis→ co mention →Quarter For Gilead Sciences64 evidence records
- Morgan Stanley→ co mention →Quarter For Gilead Sciences56 evidence records
- Sun Pharmaceuticals On→ co mention →Quarter For Gilead Sciences53 evidence records
- Avidity Biosciences Company Profile→ co mention →Quarter For Gilead Sciences50 evidence records
- Quarter For Gilead Sciences→ co mention →Novo Nordisk49 evidence records
- Merck Co→ co mention →Quarter For Gilead Sciences48 evidence records
- Eboog Johnson→ co mention →Quarter For Gilead Sciences46 evidence records
- Reuters→ co mention →Quarter For Gilead Sciences46 evidence records
- Abbvie Inc→ co mention →Quarter For Gilead Sciences45 evidence records
- Vertex Pharmaceuticals Incorporated→ co mention →Quarter For Gilead Sciences45 evidence records
- York To Royal Bank→ co mention →Quarter For Gilead Sciences45 evidence records
- Goldman Sachs Group Inc→ co mention →Quarter For Gilead Sciences43 evidence records
- Cantor Fitzgerald→ co mention →Quarter For Gilead Sciences42 evidence records
- Citigroup→ co mention →Quarter For Gilead Sciences41 evidence records
- Venclexta Venclyxto→ co mention →Quarter For Gilead Sciences41 evidence records
- Barclays→ co mention →Quarter For Gilead Sciences40 evidence records
- Linkedin→ co mention →Quarter For Gilead Sciences38 evidence records
- Donald Trump→ co mention →Quarter For Gilead Sciences38 evidence records
Ask this desk
Desk analyst
Read-only questions about Quarter For Gilead Sciences's stored record. Answers cite only records retrieved for that turn; a citation chip opens the existing inspection view. Absence of matches is not evidence of inactivity.
Operator sign-in is required. Sign in